AUTHOR INDEX

Note: Page numbers starting with "S" are found in Supplement 1, March-April 2001.

Ackerman, L., 259
Aikawa, K., 477
Alamgir, F., 433
Ankersmit, J.-H., 67
Anziano, R.J., S1
Argenziano, M., 55
Atwood, J.E., 259

Barbone, A., 19
Barbut, D., 101
Bateman, T.M., 197
Bednar, M.M., S1
Berman, D.S., 215
Bonser, R.S., 373
Bornstein, A., 335
Brown, K.A., 231
Burkhoff, D., 19

Camici, P.G., 399
Camm, A.J., S1
Cao, Y., 113
Caplan, L.R., 101
Carabello, B.A., 457
Chaudhry, F.A., 351
Chee, N.K., 197
Chiarello, M., 419
Clark, A.L., 433
Clark, R.E., 95
Cleland, J.G.F., 433
Crouse, L.J., 303

Dave, R.M., 231
Dembitsky, W.P., 5
Dickstein, M.L., 47
Dowling, R.D., 27
Dutka, D.P., 399

Etoch, S.W., 27
Evans, R.W., 81

Froelicher, V., 259

Gorman, M., 135
Gottdiener, J.S., 275, 315
Grayburn, P.A., 245

Hachamovitch, R., 215
Harrigan, E.P., S1
Heath, M.J.S., 47
Helman, D.N., 1
Hoercher, K., 37
Holmes, J.W., 19

Itescu, S., 67

James, T.N., 495
Jaski, B.E., 5

Kocher, A.A., 67
Kramer, P.H., 303
Kübler, W., 171

Laskar, R., 245
Lewis, ME., 373
Lewis, W., 151
Lingle, R.J., 5
Llinas, R., 101

McCarthy, P.M., 37
Madigan, J., 19
Melin, J.A., 387
Morales, D.L.S., 55

Nagesh, V., 113
Nikitin, N.P., 433
Norell, M., 433

Opie, L.H., 171
Oz, M.C., 19, 55

Perrone-Filardi, P., 419
Pitt, M., 373

Quaglietti, S.E., 259
Qureshi, E.A., 335

Reardon, L.C., 5
Rose, E.A., 1
Rosman, D.R., 231
Rozanski, A., 275, 281, 335, 363
Ruskin, J.N., S1

Schuster, M.D., 67
Shaw, L., 215
Singh, B.K., 351

Vanoverschelde, J.-L.J., 387

Welch, K.M.A., 113

Yao, S.-S., 281
Yusuf, S., 171

Zafirelis, Z., 95

SUBJECT INDEX

Note: Page numbers starting with "S" are found in Supplement 1, March/April 2001.

ABCD (Appropriate Blood Pressure Control in Diabetes) Trial, 183, 185
Acquired immunodeficiency syndrome. *See* Human immunodeficiency virus infection
Adenosine
  in echocardiography, 323-324
  in nuclear perfusion studies, vs. exercise, 284
AIDS. *See* Human immunodeficiency virus infection
Air, in contrast echocardiography. *See* Echocardiography, contrast
Air embolism, with left ventricular assist device, 43-44
Alcohol abuse, cardiomyopathy due to, in AIDS, 152-154
ALLHAT (Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial), 183
Amiodarone
  in ischemic heart failure, 444
  QT interval prolongation due to, S18, S34
Amitriptyline, QT interval prolongation due to, S20
Amlodipine
  in ischemic heart failure, 444-445

Amlodipine (*Continued*)
safety of
in angina, 176
in heart failure, 184, 186
in hypertension, 181-183, 185
in stable angina, 175
in vascular disease, 179
Ammonia, nitrogen-13 labeled, in PET, of myocardial ischemia, 403, 405-406
Anderson, R.H., internodal pathway studies of, 498
Anesthesia
encephalopathy due to, in cardiac surgery, 102
for left ventricular assist device placement, 49
Angina
in aortic regurgitation, 470
in aortic stenosis, 479
chronic stable effort, calcium channel blocker safety in, 173-175
history of, in preoperative cardiac event prediction, 292-293
unstable
calcium channel blocker safety in, 174-177
myocardial perfusion scintigraphy in, 287-288
Angina Prognosis Study in Stockholm, 173
Angiogenesis, in cardiomyopathy, in AIDS, 157
Angiography
carotid, emboli formation in, transcranial Doppler assessment of, 144-145
coronary. *See* Coronary angiography
Angioplasty
carotid, emboli formation in, transcranial Doppler assessment of, 144-145
coronary. *See* Coronary angioplasty
Angiotensin-converting enzyme inhibitors, in ischemic heart failure, 437-440
Angiotensin receptor antagonists, in ischemic heart failure, 440
Annihilation coincidence detection, in positron emission tomography, 400
Anoxic brain injury, in cardiac surgery, 103-104
Anticoagulants
in embolism management, 145
in ischemic heart failure, 445-448
Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial, 183
Antiplatelet agents, in embolism management, 145
Antipsychotics, QT interval prolongation due to, S34
Antiretroviral therapy, for AIDS, cardiomyopathy and, 157-158
Anuloaorticectasia, aortic regurgitation in, 468
Aorta, cross-clamping of, emboli derived from, 106-107
Aortic balloon counterpulsation, in mitral regurgitation, 466
Aortic regurgitation, 468-472
acute, 471-472
Aortic regurgitation (*Continued*)
clinical features of, 470
etiology of, 468-469
pathophysiology of, 469-470
physical examination in, 470
severity of, assessment of, 470-471
treatment of, 471-472
Aortic stenosis, 477-493
asymptomatic
clinical outcome in, 478-479
severe, valve replacement in, 488-489
sudden death risk in, 478, 489
causes of, 477-478
in elderly persons, 485-488
hemodynamic progression rate in, 478
with left ventricular systolic dysfunction, 483-485
medical therapy for, 490
mild to moderate, valve replacement in, during coronary revascularization, 489-490
natural history of, 477-479
stress echocardiography in, 325
symptomatic
clinical outcome in, 479-481
valve replacement in, 480, 482-483
Aortic valve, replacement of
in regurgitation, 471-472
in stenosis, 480, 482-483
mild to moderate, 489-490
severe, 488-489
AP-SIS (Angina Prognosis Study in Stockholm), 173
Aphasia
in cardiac surgery, 105
in stroke, magnetic resonance imaging of, 130-133
Apoptosis
of conduction system components, 522-523
in postnatal morphogenesis, 517, 524
in myocardial hibernation, 382-383
of T cells, with left ventricular assist device, 72-73
Apparent diffusion coefficient of protons of water molecules (ADC_w)-signature model, for magnetic resonance imaging, of stroke, 117-122
Appropriate Blood Pressure Control in Diabetes Trial, 183, 185
Arbutamine, in echocardiography, 323
Arrhythmias. *See also* QT interval, corrected, prolongation of; *specific arrhythmias*
in cardiac surgery
embolic stroke due to, 105-106
neurologic complications of, 110
emboli from, transcranial Doppler assessment of, 141
after left ventricular assist device placement, 51-52
left ventricular assist device placement with, 39-40
Artificial heart, development of, 2-4
Aschoff, Karl Albert Ludvig, internodal pathway studies of, 495-497

ASIST (Atenolol Silent Ischemia Study), 173
Aspirin
  in embolism management, 145
  in ischemic heart failure, 445-448
Astemizole, QT interval prolongation due to, S20
Atenolol Silent Ischemia Study, 173
Atherosclerosis
  calcium channel blocker effects on, 179, 181
  embolic stroke due to, in cardiac surgery, 106-108
Atrial fibrillation, emboli from
  in cardiac surgery, stroke due to, 105-106
  transcranial Doppler assessment of, 141
Atrial flutter, following internodal pathways, 523
Atrial septum
  defect of, emboli from, transcranial Doppler assessment of, 142-143
  destruction of, internodal pathways in, 518-520
  embryology of, 520-523
Atrioventricular node
  cellular structure of, 525-526
  destruction of, 520
  embryology of, 520-523
  morphology of, 500
  transitional cells in, 516
Atrium
  left
    activation of, 504-507
    atrophy of, in arrhythmogenic right ventricular dysplasia, 518-520
    cannulation of, for extracorporeal assist devices, 28-29
  right, excitation of, pathways for, 501-503
Attenuation, in positron emission tomography, 401-402
Austin Flint murmur, in aortic regurgitation, 470
Autoimmunity, in left ventricular assist device implantation, 72-73
Azathioprine, in antibody development, with left ventricular assist device, 76

B cells, hyperreactivity of, with left ventricular assist devices, 71, 73-75
Bachmann, G., internodal pathway studies of, 496
Bachmann's bundle
  crista terminalis connection to, 503-504
  destruction of, 518
  function of, 504-505
  morphology of, 499, 502, 529-530
Basilar artery, stroke involving, in cardiac surgery, 103
Bayesian analysis, in stress testing, 368-369
Bepridil, QT interval prolongation due to, S20
Beta-blockers
  carbon-11 labeled, in positron emission tomography, of myocardial receptors, 413-414
  in ischemic heart failure, 440-443
Bicuspid aortic valve, stenosis of, 477-478
Bicycle stress echocardiography, technical considerations in, 309, 322
Bisoprolol, in ischemic heart failure, 441
Bleeding
  gastrointestinal, calcium channel blockers and, 189
  in left ventricular device placement, 42, 51, 52, 60
Blood flow. *See also* Doppler studies
  myocardial, measurement of
    in hibernation, 388-391
    PET in, 402-405
Bone cells, in heart, 512
Brachial plexopathy, in cardiac surgery, 108-109
Brain
  embolic disorders of. *See* Embolic stroke; Transcranial Doppler Assessment
  infarction of, magnetic resonance imaging of, 125-129
  injury of, in cardiac surgery. *See* Neurologic complications, of cardiac surgery
  magnetic resonance imaging of, in stroke. *See* Magnetic resonance imaging, of stroke
  swelling of, in stroke, 125-129
Brainstem stroke, in cardiac surgery, 103
Brugada syndrome, S12
Bundle branches
  embryology of, 520-523
  morphology of, 508-509
  shielding in, 526-527

Calcification, of aortic valve, stenosis in, 477-478
Calcium, metabolism of, left ventricular assist device effects on, 23-24
Calcium channel blockers
  indications for, 184
  in ischemic heart failure, 444-445
  safety of, 171-196
    cancer rate and, 189
    in chronic stable effort angina, 173-176
    in congestive heart failure, 184, 186
    evidence for, 173-174
    gastrointestinal hemorrhage and, 189
    in hypertension, 174, 181-185
    long-acting vs. short-acting, 188-199
    mortality rate related to, 184, 187-189
    in myocardial infarction, 177-179
    in unstable angina, 174-177
    in vascular disease, 179-181
    wider issues in, 190
Cancer, calcium channel blockers and, 189
Captopril, in ischemic heart failure, 438
Carbohydrates, myocardial metabolism of, positron emission tomography of, 408-413
Cardiac catheterization, in mitral regurgitation, 465-466
Cardiomyopathy, in AIDS. *See* Human immunodeficiency virus infection, cardiomyopathy in

Cardiopulmonary bypass
emboli formation during
control of, 110
transcranial Doppler assessment of, 143-144
encephalopathy due to, 104-105
history of, 1-2
for left ventricular assist device placement
separation after, 50-52
technique for, 49
Carotid arteries
embolization of
in cardiac surgery, 107-108
transcranial Doppler assessment of, 140-141
procedures on, emboli formation in, transcranial Doppler assessment of, 144-145
Cartilage, in heart, 512
Carvedilol, in ischemic heart failure, 441-443
Carvedilol Hibernation Reversible Ischemia Trial: Marker of Success, 442
CASS (Coronary Artery Surgery Study), 375-377, 448-449
Catheterization, cardiac, in mitral regurgitation, 465-466
Central fibrous body, morphology of, 500
Cerebellum, stroke of, in cardiac surgery, 103
Cerebral arteries, embolic stroke of, transcranial Doppler assessment of, 139-140
Cerebrovascular disease. *See also* Stroke
cardiac surgery in, 101-112
confusion in, 104-105, 109
not waking after, 102-104
risk assessment for, 109-110
weakness in, 105-109
transcranial Doppler assessment of. *See* Transcranial Doppler assessment
CGP 12177 beta-antagonist, in positron emission tomography, of myocardial receptors, 413-414
Chest pain. *See also* Angina
myocardial perfusion scintigraphy in, 287-288
noninvasive stress testing in, cost-effectiveness of, 202
Chlorpromazine, QT interval prolongation due to, S34
Chordae tendineae, disorders of, mitral regurgitation in, 458
CHRISTMAS (Carvedilol Hibernation Reversible Ischemia Trial: Marker of Success) study, 442
Cisapride, QT interval prolongation due to, S16-S17, S22-S23
Clarithromycin, QT interval prolongation due to, S23
Clomipramine, QT interval prolongation due to, S23
Cocaine abuse, cardiomyopathy due to, in AIDS, 154-155
Columbia-Presbyterian experience, with outpatient left ventricular assist devices, 59-65
Coma, hypoxic, in cardiac surgery, 103-104
Conduction system, postnatal morphogenesis of, 517, 524
Confusion, in cardiac surgery, 104-105, 109
Congenital long QT syndrome, S12-S13
Congestive heart failure. *See* Heart failure, congestive
Consciousness, alterations of, in cardiac surgery, 102-104
Contractility
left ventricular assist device effects on, 22-23
in mitral regurgitation, 460
Contrast echocardiography. *See* Echocardiography, contrast
Coronaryangiography,vs.stressechocardiography,cost-effectiveness of, 202, 204-205
Coronary angioplasty
in ischemic heart failure, 383
myocardial perfusion scintigraphy after, 289-290
noninvasive testing after, cost-effectiveness of, 207
Coronary artery bypass graft surgery
emboli from, transcranial Doppler assessment of, 143-144
graft stenosis in, stress echocardiography in, 326
in ischemic heart failure, 373-386, 376-377
alternatives to, 383
clinical trials of, 375-377
in left ventricular functional impairment, 376-377
myocardial hibernation and, 374-375, 380-383
myocardial viability assessment in, 375, 377-380
risks of, 382-383
myocardial perfusion scintigraphy after, 289-290
neurologic complications of, 101-112
confusion, 104-105, 109
not waking, 102-104
risk assessment for, 109-110
weakness, 105-109
noninvasive testing after, cost-effectiveness of, 207
Coronary artery disease
contrast echocardiography in, 253-254
in graft, stress echocardiography in, 326
ischemic heart failure in. *See* Heart failure, ischemic
positron emission tomography in, 405-407
stress testing in, noninvasive. *See* Stress echocardiography, vs. stress nuclear perfusion imaging
Coronary Artery Surgery Study, 375-377, 448-449
Coronary vasodilator reserve, measurement of, positron emission tomography in, 404-405
Corrigan's pulse, in aortic regurgitation, 470
Cost-effectiveness analysis, of noninvasive stress testing. *See under* Stress echocardiography, vs. stress nuclear perfusion imaging
Costs
of left ventricular assist devices, 81-94
centers of excellence and, 86-87
conceptual framework for, 82-83
vs. heart failure treatment costs, 87
limited data and experience in, 85-87

Costs (*Continued*)
outpatient, 62-63
transplant services payment methods and, 82-83
vs. transplantation, 81-91
of noninvasive stress testing. *See* Stress echocardiography, vs. stress nuclear perfusion imaging, cost-effectiveness analysis of
Crista terminalis
destruction of, 519
morphology of, 499-501, 529-530
in right atrial excitation, 501-503
Cyclophosphamide, in antibody development, with left ventricular assist device, 75-76
Cyclosporine, in antibody development, with left ventricular assist device, 76
Cytokine profile
in cardiomyopathy, in AIDS, 155-156
with left ventricular assist devices, 71

Danish Verapamil Infarction Trial (DAVIT), 177-179
de Musset's sign, in aortic regurgitation, 470
Dementia, cardiac surgery in, confusion in, 104
Depolarization, in QT interval, S2
Desipramine, QT interval prolongation due to, S23
Destination therapy, with left ventricular assist devices, 95-96
Diabetes mellitus
hypertension in, calcium channel blocker safety in, 181, 183
in preoperative cardiac event prediction, 292-293
QT interval prolongation in, S13, S15
Diastolic function, in mitral regurgitation, 462-463
Digoxin, in ischemic heart failure, 436-437
Diltiazem
in ischemic heart failure, 444-445
safety of
in angina, 175-177
in heart failure, 186
in hypertension, 182-183
mortality rate and, 187-188
in myocardial infarction, 177-179
Dipyridamole
in echocardiography, 323-324, 353-354
in nuclear perfusion studies
vs. exercise, 284
in noncardiac surgery preoperative assessment, 290-291, 293
technical considerations in, 311
Disopyramide, QT interval prolongation due to, S18
Diuretics
in ischemic heart failure, 436
in mitral regurgitation, 466
Dobutamine
in cardiopulmonary bypass separation, in left ventricular assist device placement, 50
Dobutamine (*Continued*)
in echocardiography, 323-324
for aortic stenosis evaluation, 483-484
for myocardial viability assessment, 352-358, 424-427
in nuclear perfusion studies
vs. exercise, 284
technical considerations in, 309-311
Doppler studies
of aortic regurgitation, 470-471
in contrast echocardiography, 248
of mitral regurgitation, 464-465
in stress echocardiography, 316-318
transcranial. *See* Transcranial Doppler assessment
Doxepin, QT interval prolongation due to, S24
Drugs
encephalopathy due to, in cardiac surgery, 102
QT interval prolongation due to, S15-S34
Duroziez's sign, in aortic regurgitation, 470
Durrer, Dirk, internodal pathway studies of, 497-498
Dyspnea
in aortic regurgitation, 470
in aortic stenosis, 479
in mitral regurgitation, 463

Echocardiography
contrast, 245-258
in acute myocardial infarction, 253
agents for, 246, 253-254
in coronary artery disease, 253-254
future of, 255
harmonic imaging in, 247-248
intermittent imaging in, 246-247
in myocardial viability testing, 254-255, 354, 358, 425-426
perfusion prediction in, 250-251
physiology of, 248-250
power Doppler harmonic imaging in, 248
principles of, 245-246
technical considerations in, 311-312
Doppler
in aortic regurgitation, 470-471
of mitral regurgitation, 464-465
in postexercise left ventricular function assessment, 341-342
stress. *See* Stress echocardiography
transesophageal, in left ventricular assist device placement, 49-50
Economic impact. *See* Costs
ECSS (European Coronary Surgery Study), 375-376
Effective regurgitant orifice area, measurement of, in aortic regurgitation, 470
Ejection fraction
in aortic regurgitation, 469-470

Ejection fraction (*Continued*)
in gated SPECT, 283-284
as myocardial viability standard, 420-421
Elderly persons
aortic stenosis in, 485-488
preoperative cardiac event prediction in, 292-293
Electric Boat Company, left ventricular assist device of, 96
Electrocardiography
in aortic regurgitation, 470
in mitral regurgitation, 463-464
QT interval in. *See* QT interval
stress
vs. nuclear perfusion pharmacologic testing, 284, 286-289
prognostic value of
in jeopardized viable myocardium detection, 233
principles of, 232
vs. stress echocardiography, cost-effectiveness of, 202-204, 206-207
in stress echocardiography, 305-307
Electroencephalography, in hypoxic brain injury, 104
ELITE (Evaluation of Losartan in the Elderly), on angiotensin receptor antagonists, 440
Emboli, small, ultrasound signals from. *See* Microembolic signals
Embolic stroke
in cardiac surgery
bypass-related, 104-105
confusion in, 109
posterior, 103
weakness in, 105-108
magnetic resonance imaging of. *See* Magnetic resonance imaging, of stroke
transcranial Doppler assessment of. *See* Transcranial Doppler assessment
Emergency room, chest pain evaluation in, with myocardial perfusion scintigraphy, 294-295
Enalapril, in ischemic heart failure, 438-439
Encephalopathy, in cardiac surgery
confusion in, 104-105
toxic/metabolic, 102
End-diastolic pressure-volume relationship, left ventricular assist device effects on, 21
Endarterectomy, carotid, emboli formation in, transcranial Doppler assessment of, 144-145
Endocarditis, aortic regurgitation in, 471-472
Endothelial cells, changes of, in cardiomyopathy, in AIDS, 156-157
Endothelin-1, in cardiomyopathy, in AIDS, 155-156
Endpoints, selection of, for outcomes research, on noninvasive stress testing, 219-220, 226-227
Erlangen, Germany, conference on internodal pathways, 496-497
Erythromycin, QT interval prolongation due to, S24-S25
Ethanol abuse, cardiomyopathy due to, in AIDS, 152-154
European Coronary Surgery Study, 375-376
Eustachian valve (ridge)
destruction of, 518
function of, 502
morphology of, 499, 501, 529-530
EVADE (experience with left ventricular assist device with exercise) trial, 6-10
Evaluation of Losartan in the Elderly, on angiotensin receptor antagonists, 440
Exercise
in heart failure, left ventricular assist device effects on, 6-8
left ventricular function after. *See* Postexercise left ventricular function
Exercise testing
in aortic stenosis, 480
echocardiographic, 305-309, 322-323
electrocardiographic, vs. nuclear perfusion pharmacologic testing, 284, 286-289
Experience with left ventricular assist device with exercise (EVADE) trial, 6-10

FACET (Fosinopril Amlodipine Cardiovascular Events Trial), 183, 185
Fatty acids, free, myocardial metabolism of, positron emission tomography of, 408-410
Felodipine
in ischemic heart failure, 444
safety of, in heart failure, 186
Flecainide, QT interval prolongation due to, S18
Flow mapping, in mitral regurgitation quantification, 464
2-Fluoro-2-deoxyglucose, in PET
for myocardial ischemia, 399, 410-413
for myocardial viability assessment, 327, 357-358
Fluoroscopy, in aortic stenosis, 484
Fosinopril, safety of, in hypertension, 183
Fosinopril Amlodipine Cardiovascular Events Trial, 183, 185
Free fatty acids, myocardial metabolism of, positron emission tomography of, 408-410

Gases, in contrast echocardiography. *See* Echocardiography, contrast
Gastrointestinal hemorrhage, calcium channel blockers and, 189
GESICA (Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina) study, 444
Glucose, myocardial metabolism of, positron emission tomography of, 327, 408-413
Grepafloxacin, QT interval prolongation due to, S25
Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina study, 444

Halofantrine, QT interval prolongation due to, S25
Haloperidol
  encephalopathy due to, in cardiac surgery, 102, 104
  QT interval prolongation due to, S25-S26, S34
Handgrip, for stress echocardiography, 322-323
Harmonic imaging, in contrast echocardiography, 247-248
Heart, transplantation of. *See* Transplantation, cardiac
Heart block, in atrioventricular node destruction, vs. His bundle destruction, 522-523
Heart failure
  in AIDS. *See* Human immunodeficiency virus infection, cardiomyopathy in
  in aortic stenosis, 479
  congestive
    calcium channel blocker safety in, 184, 186
    causes of, 259
    epidemiology of, 259
    pathophysiology of, 5-6, 47-48
    progression of, 5-6
    treatment of, 259-274
      advanced, 269
      costs of, 81-94
      end-of-life, 269-270
      follow-up methods for, 261
      future research on, 271-272
      home, 265-269
      outcomes of, 260-261
      outpatient, 261-265
      palliative, 269-270
  ischemic
    clinical features of, 434-435
    coronary artery surgery for, 373-386
    epidemiology of, 373
    medical management of, 433-455
      amiodarone in, 444
      angiotensin-converting enzyme inhibitors in, 437-440
      antithrombotic measures in, 445-448
      beta-blockers in, 440-443
      calcium antagonists in, 444-445
      with coronary artery disease, 445-449
      diagnosis for, 435-436
      digoxin in, 436-437
      diuretics in, 436
      lipid-lowering therapy in, 448
      vs. revascularization in, 448-449
      smoking cessation in, 445
      spironolactone in, 443
      standard, 436-437, 445-449
      targets for, 434-435
      vasodilators in, 444
    mitral regurgitation in, surgical treatment of, 468
    myocardial hibernation in
      identification of, 419-432
Heart failure (*Continued*)
      physiology of, 387-398
    pathophysiology of, 373-374, 434-435
    positron emission tomography in, 399-418
    progression of, 434
  mechanical circulatory support for, 1-4. *See also* Left ventricular assist devices
Heart Outcomes Prevention Evaluation study, on ischemic heart failure, 439, 446, 448
Heart rate, QT interval variation with, S3-S4
Heartmate assist devices
  description of, 37-41
  indications for, 41-42
  placement of, complications of, 42-44
  quality of life with, 42
  survival with, 44-45
Hemodialysis, immunologic response to, 68
Hemodynamics, left ventricular assist device effects on
  exercise, 6-8
  resting, 6
Hemorrhage. *See* Bleeding
Hibernation, myocardial. *See* Myocardial hibernation
High-intensity transient signals. *See* Microembolic signals
Hill's sign, in aortic regurgitation, 470
HINT (Holland Inter-University Nifedipine) Study, 175-176
His, Wilhelm, Jr., internodal pathway studies of, 495
His bundle
  embryology of, 520-523
  morphology of, 508-509
  shielding in, 526-527
Holland Inter-University Nifedipine Study, 175-176
Holter monitoring, in QT interval measurement, S3
Home care, of heart failure, 265-269
HOPE study, on ischemic heart failure, 439, 446, 448
Hospice care, for end-stage heart failure, 269-270
HOT (Hypertension Optimal Treatment) study, 181, 185
Human immunodeficiency virus infection, cardiomyopathy in, 151-170
  animal models of, 161-163
  antiretroviral therapy and, 157-158
  comorbid conditions with, 152-155
  cytokines in, 155-156
  direct retroviral involvement in, 160-161
  epidemiology of, 151-152
  left ventricular dysfunction in, 158-159
  myocarditis preceding, 159-160
  nutritional deficiency and, 159
  pathogenesis of, 152
  vascular changes in, 156-157
Human leukocyte antigens, antibodies to, with left ventricular assist devices, 71-73
Hydralazine, in ischemic heart failure, 444

Hydrocephalus, in cardiac surgery, 103
Hydroxyephedrine, carbon-11 labeled, of myocardial receptors, 414
Hypertension, calcium channel blocker safety in, 174, 181-185
Hypertension Optimal Treatment study, 181, 185
Hypotension, in cardiac surgery, neurologic complications of, 110
Hypovolemia, in left ventricular device placement, 52
Hypoxemia
  in cardiac surgery, brain injury in, 103-104
  in left ventricular device placement, 52

Imipramine, QT interval prolongation due to, S26
Immune deficiency. *See also* Human immunodeficiency virus infection
  with left ventricular assist devices, 70-71
Immunobiology, of left ventricular assist devices, 67-80
  autoimmune response, 72-73
  B-cell hyperreactivity, 71, 73-75
  clinical relevance of, 72-73
  cytokine profile, 71
  immune deficiency, 70-71
  monocyte/macrophage deposition, 68
  systemic consequences, 69-70
  T-cell interactions, 68-71, 73-75
  therapeutic interventions, 75-77
Immunoglobulin, intravenous, in antibody development, with left ventricular assist device, 75-76
Incomplete Infarction Trial of European Research Collaborators Evaluation Prognosis Postthrombolysis study, 178-179
Incremental prognostic value, in outcomes research, on noninvasive stress testing, 220-221
Infections
  encephalopathy in, in cardiac surgery, 102
  in left ventricular device placement, 42-44, 60-61
    due to immune deficiency, 73-74
Inotropic agents, in cardiopulmonary bypass separation, in left ventricular assist device placement, 50-51
INTACT (International Nifedipine Trial on Antiatherosclerotic Therapy), 179-180
INTERCEPT (Incomplete Infarction Trial of European Research Collaborators Evaluation Prognosis Postthrombolysis) study, 178-179
Interferon(s), in cardiomyopathy, in AIDS, 155-156
Interleukin(s), in cardiomyopathy, in AIDS, 155-156
Intermittent imaging, in contrast echocardiography, 246-247
International Nifedipine Trial on Antiatherosclerotic Therapy, 179-180
Internodal pathways, 495-535
  anisotropy in, 507-508
  anterior, 506
Internodal pathways (*Continued*)
  distal, 506
  historical studies of, 495-498
  middle, 506
  morphology of, 499, 501-506
    vs. functional considerations, 506-508
  Purkinje cells in, 511-514
    vs. transition cells, 508-511, 515-516, 530
  shielding in, 526-528
  specialized cells in, 516-526
  synchronization of, 506-508
  transition cells in
    vs. Purkinje cells, 508-511, 515-516
    special function of, 527, 529-530
Intra-aortic balloon pump, history of, 2
Ionic currents, QT interval and, S2
Ischemia, myocardial. *See* Myocardial ischemia
Ischemic stroke
  embolic. *See* Embolic stroke
  magnetic resonance imaging of. *See* Magnetic resonance imaging, of stroke
Isradipine, safety of
  in hypertension, 181, 183, 185
  in vascular disease, 180

James fibers, 502
Janse, M.J., internodal pathway studies of, 498
Jervell—Lange-Nielsen syndrome, S12-S13
Jet size, measurement of
  in aortic regurgitation, 470
  in mitral regurgitation, 464
Jet velocity, in aortic stenosis, 479, 489
JT interval, within QT interval, S2, S6
Jugular vein, thrombosis of, transcranial Doppler assessment of, 145

Keith, Sir Arthur, internodal pathway studies of, 495
Kent, Stanley, internodal pathway studies of, 495
Kidney, left ventricular assist device effects on, 8-10
Koch, Walter, internodal pathway studies of, 495-497

Left ventricle(s)
  dilation of, in radionuclide studies, 282-283
  dysfunction of
    in AIDS, 158-159
    in aortic stenosis, 483-485, 488-489
    coronary artery bypass graft surgery in, 376-377
    in mitral regurgitation, 460-461, 467-468
    myocardial blood flow in, positron emission tomography of, 407-408
    reversible. *See also* Myocardial hibernation
      echocardiography in, 351-352
    stress echocardiography in, 319-320
  function of. *See* Postexercise left ventricular function
  hypertrophy of

Left ventricle(s) (*Continued*)
in aortic regurgitation, 469
in aortic stenosis, 488
in mitral regurgitation, 460-461
reverse remodeling of, with left ventricular assist device, 19-26
systolic function of
in aortic stenosis, 488
as myocardial viability standard, 421
transient ischemic dilation of, 342-344
unloading of, with left ventricular assist device, 20
volume of, in gated SPECT, 283-284
wall motion abnormalities in, stress echocardiography of, 346-347
wall thickening of, segmental, stress echocardiography in, 320-321
Left ventricular assist devices
as bridge to recovery, 5-18
future of, 98-99
outpatient, 55-66
as bridge to transplantation
economic impact of, 81-94
future of, 96-97
outpatient, 55-66
reverse remodeling in, 19-26
complications of, 42-44, 60-62, 67-80
costs of, 62-63, 81-94
in destination therapy, 95-96
extracorporeal, 27-36
ABIOMED BVX-5000, 28-29, 33-35
advantages of, 27-29
disadvantages of, 29
Thoratec, 28-33
failure of, 44, 65-66
functional recovery with, 5-18
exercise tolerance effects of, 6-8
explantation after, 13-16
heart structural effects of, 11
metabolic effects of, 11
myocyte effects of, 11-13
neurohormonal effects of, 11
noncardiac organ effects of, 8-11
pre-existing abnormalities and, 5-6
quality of life and, 8
resting hemodynamic effects of, 6
future of, 95-100
history of, 1-4
immunobiology of, 67-80
indications for, 41-42
inexpensive, 99-100
intracorporeal, 37-46
complications of, 42-44
description of, 37-41
indications for, 41-42
physiologic aspects of, 37-41
Left ventricular assist devices (*Continued*)
quality of life with, 42
survival with, 44-45
malfunction of, 65-66
outpatient, 55-66
physiologic aspects of, 37-41
placement of, 47-54
anesthesia induction in, 49
assessment before, 48-49
cardiopulmonary bypass separation after, 50-52
complications of, 42-44
pathophysiologic considerations in, 47-48
postoperative management in, 52
Thoratec, 30-31
timing of, 41
transesophageal echocardiography in, 49-50
vascular cannulation for, 49
quality of life with, 42, 63-65
reverse ventricular remodeling due to, 19-26
short-term use of, 99-100
support modes for, 31-32
survival with, 44-45
Lewis, Thomas, internodal pathway studies of, 497
Lionhearted left ventricular assist device, 96
Lipid-lowering therapy, for ischemic heart failure, 448
Lisinopril, in ischemic heart failure, 438
Liver, left ventricular assist device effects on, 8-10
Long QT syndrome, congenital, S12-S13
Losartan, in ischemic heart failure, 440
Lown-Ganong-Levine syndrome, pathophysiology of, 502-503
Lung
left ventricular assist device effects on, 8-9
radionuclide uptake of, in coronary artery disease, 282
LVADs. *See* Left ventricular assist devices

Mackenzie, Ivy, internodal pathway studies of, 497
Macrophages, deposition of, on left ventricular assist device surfaces, 68
Magnetic resonance imaging, of stroke, 113-134
acute, 115-117
advanced techniques for, 114-115
advantages of, 113-114
apparent diffusion coefficient of protons of water molecules (ADC_w)-signature model for, 117-122
contrast agents for, 115
diffusion-weighted, 114-115
in evolution from ischemia to infarction, 125-129
perfusion-weighted, 114-115
principles of, 114
in prognosis assessment, 132-133
in recovery, 130-133
three dimensional tissue signature model for, 122-125

Major histocompatibility complex, antibodies to, with left ventricular assist devices, 71-73
Mechanical circulatory support. *See also* Left ventricular assist devices
  history of, 1-4
Metabolic encephalopathy, in cardiac surgery, 102
Metabolism, left ventricular assist device effects on, 11
Metoprolol, in ischemic heart failure, 441
Mibefradil, QT interval prolongation due to, S34
Microbubbles, in contrast echocardiography. *See* Echocardiography, contrast
Microembolic signals, in Doppler monitoring, 135
  vs. artifacts, 136-138
  of cardiac emboli, 141-143
  vs. emboli type, 138-139
  in extracranial disease, 140-141
  in intracranial disease, 139-140
  procedure-related, 143-145
  in retinal ischemia, 139
  in stroke, 139
  in treatment monitoring, 145
  in venous thrombosis, 145
MIDAS (Multicenter Isradipine Diuretic Atherosclerosis) study, 180-181, 185
Milrinone, in cardiopulmonary bypass separation, in left ventricular assist device placement, 50
Mitral regurgitation, 457-468
  acute, 458-460, 463-464
  asymptomatic, treatment of, 467-468
  cardiac catheterization in, 465-466
  chronic, 459-460, 464
  clinical features of, 463-464
  decompensation in, 459-460, 464
  diastolic function in, 462-463
  ischemic, treatment of, 468
  left ventricular dysfunction in, 460-461, 468
  mechanism of, 457-458
  with normal left ventricular function, treatment of, 467
  pathophysiology of, 458
  primary, 457
  quantification of, 464-465
  secondary, 457
  treatment of, 466-468
Mitral stenosis, stress echocardiography in, 325
Mitral valve, repair or replacement of, in regurgitation, 466-468
Mönckeberg, J.G., internodal pathway studies of, 496-497
Monocytes, interactions of, with left ventricular assist device surfaces, 68-69
Moricizine, QT interval prolongation due to, S19
Mortality. *See also* Sudden death
  calcium channel blocker-related, 184, 187-189
Moxifloxacin, QT interval prolongation due to, S26
MRI. *See* Magnetic resonance imaging
Multicenter Isradipine Diuretic Atherosclerosis study, 180-181, 185
Multiple organ failure, left ventricular assist device implantation and, 40-41
Multivariable modeling, in outcomes research, on noninvasive stress testing, 216
Murmurs
  in aortic regurgitation, 470
  in aortic stenosis, 478
Myocardial contrast echocardiography. *See* Echocardiography, contrast
Myocardial hibernation
  definition of, 388
  histology of, 380-381
  identification of, 419-432
    contrast echocardiography in, 425-426
    dobutamine echocardiography in, 424-427
    echocardiography in, 352, 355-356
    gold standard for, 420-421
    noninvasive testing in, cost-effectiveness of, 208-209
    nuclear techniques in, 421-425
    prognosis and, 426-428
    regional systolic function recovery in, 421
  in ischemic heart failure, 374-375, 380-383
  pathophysiology of, 387-398
    animal models of, 390-391
    blood flow, 388-391
    clinical implications of, 393-394
    future directions in, 394
    morphologic, 391-393
  positron emission tomography of, 407-408, 410-413
  revascularization in, clinical outcome after, 426
  short-term, 390-391
Myocardial infarction
  acute, contrast echocardiography in, 253
  calcium channel blocker safety in, 177-179
  ischemic heart failure in. *See* Heart failure, ischemic
  myocardial perfusion scintigraphy after, 288-289
  noninvasive testing after, cost-effectiveness of, 206-207
  QT interval prolongation after, S13-S14
  shock in, left ventricular assist device placement in, 41-42
Myocardial ischemia
  heart failure in. *See* Heart failure, ischemic
  left ventricular dilation in, 342-344
  noninvasive stress testing in, 201-206
  nuclear studies of. *See* Myocardial perfusion, nuclear
  stress echocardiography in. *See* Stress echocardiography
  viability in. *See* Myocardial viability
Myocardial perfusion
  contrast echocardiography of. *See* Echocardiography, contrast
  nuclear, 281-302
    after angioplasty, 289-290

Myocardial perfusion (*Continued*)
clinical applications of, 287-295
after coronary artery bypass surgery, 289-290
cost-effectiveness of, 286-287, 295-296
defect reversibility in, 283
vs. echocardiography. *See* Stress echocardiography, vs. stress nuclear perfusion imaging
in emergency room, 294-295
equivocal results of, prognostic value of, 285-286
exercise vs. pharmacologic, 284
in known coronary artery disease, 284-287
after myocardial infarction, 288-289
in noncardiac surgery preoperative assessment, 290-294
normal results of, prognostic value of, 285-286
outcomes research on, 295-296
pharmacologic vs. exercise, 284
prognostic value of, 282-287
in risk characterization, 281-284, 287-294
in stable chest pain, 287
with stress echocardiography, in single laboratory service, 363-372
in unstable angina, 287-288
in viability assessment, 326-327
in women, 294
Myocardial viability
assessment of
echocardiography in, 351-361
contrast, 254-255, 425-426
dipyridamole, 353-354
dobutamine, 352-353, 357-358, 424-427
in hibernation, 352
nitroglycerine, 354
vs. other methods, 357-358
reversible left dysfunction mechanisms and, 352-356
for risk stratification, 356-357
in stunning, 352, 354-355
gold standard for, 420-421
in ischemic heart failure, 375, 377-380
noninvasive methods for, 233
nuclear techniques in, 421-425
positron emission tomography in, 411-413
prognostic value of, 426-428
after revascularization, 426
degree of, outcome of, 379-380
in hibernating myocardium. *See* Myocardial hibernation
prevalence of, in ischemic heart failure, 377-378
prognostic value of, in noninvasive testing, 232-236
stress echocardiography in, 326-327
survival and, in ischemic heart failure, 378-379
Myocarditis, in AIDS, cardiomyopathy development from, 159-160
Myocardium. *See also* Myocardial
blood flow of, measurement of
Myocardium (*Continued*)
in hibernation, 388-391
PET in, 402-405
metabolism of, positron emission tomography of, 408-410
oxygen consumption of, positron emission tomography of, 409-410
receptors of, positron emission tomography of, 413-414
stunned, viability assessment of, 352, 354-355
viability of. *See* Myocardial viability
Myoclonus, in cardiac surgery, 104
Myocytes
degeneration of, in hibernation, 382
left ventricular assist device effects on, 11-13
structure of, in hibernation, 391-393
working, morphology of, 523-524

National Institutes of Health, left ventricular assist device of, 96
Nerve injury, in cardiac surgery, 108-109
Neurologic complications, of cardiac surgery, 101-112
confusion, 104-105, 109
not waking, 102-104
risk assessment for, 109-110
weakness, 105-109
Nicardipine, safety of
mortality rate and, 188-189
in vascular disease, 180
Nifedipine
in aortic regurgitation, 472
safety of, 184
in angina, 173, 175-176
in hypertension, 181-182, 185
mortality rate and, 187-189
in myocardial infarction, 177-179
in vascular disease, 180
Nisoldipine, safety of
in heart failure, 186
in hypertension, 183
in myocardial infarction, 177
Nitrates, in ischemic heart failure, 444
Nitrendipine, safety of, in hypertension, 181
Nitric oxide
in cardiomyopathy, in AIDS, 155-156
in cardiopulmonary bypass separation, in left ventricular assist device placement, 50
Nitroglycerine, in echocardiography, 354
Nitroprusside, in mitral regurgitation, 466
Noncardiac surgery, preoperative assessment for, myocardial perfusion scintigraphy in, 290-294
Nortriptyline, QT interval prolongation due to, S27
Novacor assist device
description of, 38-41
indications for, 41-42
placement of, complications of, 42-44

Novacor assist device (*Continued*)
quality of life with, 42
survival with, 44-45
Nuclear perfusion imaging, myocardial. *See* Myocardial perfusion, nuclear
Nutritional deficiency, in AIDS, cardiomyopathy and, 159

Obesity, QT interval prolongation in, S15
Occipital lobe, stroke of, in cardiac surgery, 103
Olanzapine, QT interval prolongation due to, S34
Orthopnea, in mitral regurgitation, 463
Os cordis, in animals, 511-512
Outcomes research
for heart failure treatment, 260-261
for myocardial perfusion scintigraphy, 295-296
for noninvasive testing. *See under* Stress echocardiography, vs. stress nuclear perfusion imaging
Outpatient care, for heart failure
clinic follow-up in, 263-265
multidisciplinary, 265
nurse-directed, 263, 265
programs for, 265
telephone follow-up in, 261-263
Outpatient left ventricular assist devices, 55-66
Columbia-Presbyterian experience with, 59-65
complications of, 60-62
costs of, 62-63
discharge protocol for, 58-59
literature review on, 56
patient education for, 57-58
program for, 57-59
quality of life with, 63-65
safety nets for, 58
Oxygen consumption, myocardial, positron emission tomography of, 409-410

P cells
description of, 524-526
vs. transitional cells, 530
Papillary muscle, ischemia of, mitral regurgitation in, 458
Passive stress echocardiography. *See* Pharmacologic stress testing
Perfluorocarbons, in contrast echocardiography. *See* Echocardiography, contrast
Perfusable tissue index, in positron emission tomography, 403
Perfusion imaging
contrast echocardiography in. *See* Echocardiography, contrast
nuclear. *See* Myocardial perfusion, nuclear
Perindopril, in ischemic heart failure, 438
Peripheral nerve injury, in cardiac surgery, 108-109
Peripheral vascular surgery, preoperative evaluation for, stress echocardiography in, 325-326

PET. *See* Positron emission tomography
Pharmacologic stress testing
in echocardiography, 323-324
for myocardial viability assessment, 352-358, 424-427
in electrocardiography
in aortic stenosis, 483-484
vs. nuclear perfusion pharmacologic testing, 284, 286-289
in nuclear perfusion studies, 309-311
vs. exercise, 284
for noncardiac surgery preoperative assessment, 290-291, 293
Phenothiazine, QT interval prolongation due to, S34
Phrenic nerve injury, in cardiac surgery, 109
Pimozide, QT interval prolongation due to, S27, S34
Plasmapheresis, in antibody development, with left ventricular assist device, 75-76
Positron emission tomography
in ischemic heart failure
absolute blood flow measurement in, 402-405
applications of, 402
in coronary artery disease, 405-407
data acquisition in, 402
detection in, 399-402
indications for, 413
isotopes used in, 399-400
metabolism and, 408-410
methodology of, 399
myocardial receptors and, 413-414
quantitative, 410
in ventricular dysfunction, 407-408
in myocardial hibernation, 388-390, 407-408, 410-413
in myocardial viability assessment, 327, 357-358
vs. stress echocardiography, cost-effectiveness of, 203
Postexercise left ventricular function, 335-350
echocardiography of, 345-347
radionuclide probe studies of, 341-342
single-photon emission computed tomography of, 342-345
ventriculography of
first-pass, 339-340
multiple-gated, 335-339
Potassium currents, QT interval and, S2
Power Doppler harmonic imaging, in contrast echocardiography, 248
PRAISE (Prospective Randomized Amlodipine Survival Evaluation Group) study, 184, 186, 444-445
Prednisone, in antibody development, with left ventricular assist device, 76
Preoperative assessment
for noncardiac surgery, myocardial perfusion scintigraphy in, 290-294

Preoperative assessment (*Continued*)
noninvasive testing in
cost-effectiveness of, 207-208
prognostic value of, 240
PREVENT (Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial), 175-176, 179-180
Procainamide, QT interval prolongation due to, S19
Propafenone, QT interval prolongation due to, S19
Prospective Randomized Amlodipine Survival Evaluation Group study, 184, 186, 444-445
Prospective Randomized Evaluation of the Vascular Effects of Norvasc Trial, 175-176, 179-180
Prospective Randomized Study of Ventricular Failure and the Efficacy of Digoxin trial, 436
Prosthetic heart valves
in aortic regurgitation, 471-472
in aortic stenosis
asymptomatic, 488-489
in elderly persons, 485-488
mild to moderate, during coronary revascularization, 489-490
symptomatic, 480, 482-483
emboli from, transcranial Doppler assessment of, 141-142, 143-144
in mitral regurgitation, 466-468
PROVED (Prospective Randomized Study of Ventricular Failure and the Efficacy of Digoxin) trial, 436
Proximal isovelocity surface area method, in mitral regurgitation quantification, 464-465
Purkinje, Jan Evangelista, internodal pathway studies of, 495, 496
Purkinje cells
in bundle branches, 509-510
description of, 511-515
vs. transitional cells, 508-511, 515-516, 530
tumors of, 513-514

Q wave, in preoperative cardiac event prediction, 292-293
QRS complex, within QT interval, S2
QT interval, S1-S45
corrected, S3-S5
assessment of, S4, S6
formulas for, S5
maximum change from baseline, S6
mean change from baseline, S6
normal range of, S3
prolongation of, S7-S34
in cardiac disease, S12-S13
in diabetes mellitus, S13, S15
drug-induced, S15-S34
in myocardial infarction, S14
in obesity, S15
QT interval (*Continued*)
overview of, S7
pathophysiology of, S12-S13
population-based studies of, S7-S12
variables affecting, S7
vs. corrected QT interval, dispersion of, S6
measurement of, S2-S3
physiology of, S2
Quality of life, with left ventricular assist devices, 8, 42, 63-65
Quetiapine, QT interval prolongation due to, S27
QUIET (Quinapril Ischemic Event Trial), on angiotensin-converting enzyme inhibitors, 439
Quinapril Ischemic Event Trial, on angiotensin-converting enzyme inhibitors, 439
Quinidine, QT interval prolongation due to, S19-S20
Quinke's pulse, in aortic regurgitation, 470

RADIANCE (Randomized Assessment of the Effect of Digoxin on Inhibitors of the Angiotensin-Converting Enzyme Study), for heart failure treatment, 436
Radionuclide studies
myocardial perfusion imaging. *See* Myocardial perfusion, nuclear
in myocardial viability assessment, 421-424
with probe, in postexercise left ventricular function assessment, 341-342
ventriculography, in postexercise left ventricular function assessment
first-pass, 339-340
multiple-gated, 335-339
RALES (Randomized Aldactone Evaluation Study), in ischemic heart failure, 443
Ramipril, in ischemic heart failure, 438
Randomized Aldactone Evaluation Study, in ischemic heart failure, 443
Randomized Assessment of the Effect of Digoxin on Inhibitors of the Angiotensin-Converting Enzyme Study, for heart failure treatment, 436
Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure trial, 5
Receptors, myocardial, positron emission tomography of, 413-414
Regression analysis, in outcomes research, on noninvasive stress testing, 216
Rehabilitation, cardiac, with left ventricular assist device, 7-8
REMATCH (Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure) trial, 5
Remodeling
cytokines in, 155-156

Remodeling (*Continued*)
ventricular, reverse, with left ventricular assist device, 19-26
Repolarization, in QT interval, S2
Resource use, measurement of, in outcomes research, on noninvasive stress testing, 228
Retinal ischemia, transcranial Doppler assessment of, 139
Revascularization. *See also specific techniques, e.g.,* Coronary angioplasty
aortic valve replacement during, 489-490
in ischemic heart failure, vs. medical management, 448-449
in myocardial hibernation
ejection fraction and, 420-421
physiology of, 387, 392, 394
myocardial viability assessment after, 426-428
positron emission tomography after, 406-407
Rheumatic heart disease, aortic stenosis in, 477-478
Risk stratification, in outcomes research, on noninvasive stress testing, 221-223
Risperidone, QT interval prolongation due to, S28, S34
Romano—Ward long QT interval syndrome, S12-S13
RR interval, QT interval variation with, S3-S4

Safety, of calcium channel blockers. *See under* Calcium channel blockers
Saphenous nerve injury, in cardiac surgery, 109
Sarcoplasmic reticular calcium adenosine triphosphatase, left ventricular assist device effects on, 23-24
SAVE (Survival and Ventricular Survival) study, 188
Scandinavian Simvastatin Survival Study, 448
Scatter, in positron emission tomography, 401
Scintigraphy. *See* Radionuclide studies
Sclerosis, aortic, 478
Seizures, in cardiac surgery, 104
Sertindole, QT interval prolongation due to, S28
Shanghai Trial of Nifedipine in the Elderly study, 181, 185
SHEP (Systolic Hypertension in the Elderly Program), 183
Shielding, in internodal pathways, 526-528
Shunts, right-to-left, emboli from, transcranial Doppler assessment of, 142-143
Simvastatin, in ischemic heart failure, 448
Single-photon emission computed tomography, 281-302
after angioplasty, 289-290
clinical applications of, 287-295
vs. contrast echocardiography, 251
after coronary artery bypass surgery, 289-290
cost-effectiveness of, 286-287, 295-296
defect reversibility in, 283
in emergency room, 294-295
equivocal results of, prognostic value of, 285-286
Single-photon emission computed tomography (*Continued*)
exercise vs. pharmacologic, 284
gated, 283-284
in known coronary artery disease, 284-287
after myocardial infarction, 288-289
in noncardiac surgery preoperative assessment, 290-294
normal results of, prognostic value of, 285-286
outcomes research on, 295-296
pharmacologic vs. exercise, 284
in postexercise left ventricular function assessment, 342-344
prognostic value of, 282-287
radionuclide markers used in, 282-283
in risk characterization, 281-284, 287-294
in stable chest pain, 287
vs. stress echocardiography
cost-effectiveness of, 202-204, 223-227
principles of, 232
in unstable angina, 287-288
in viability assessment, 327
in women, 294
Sinus node
crista terminalis connections to, 503-504
destruction of, 520
embryology of, 520-523
morphology of, 500
transitional cells in, 516
Smoking cessation, in ischemic heart failure, 445
Sodium-calcium exchanger, left ventricular assist device effects on, 23-24
SOLVD (Studies of Left Ventricular Dysfunction), 188, 438, 446-448
Sotalol, QT interval prolongation due to, S20
Sparfloxacin, QT interval prolongation due to, S28-S29
SPECT. *See* Single-photon emission computed tomography
Spironolactone, in ischemic heart failure, 443
STONE (Shanghai Trial of Nifedipine in the Elderly) study, 181, 185
STOP (Swedish Trial in Old Patients) with Hypertension, 172-173, 181, 185
Stress echocardiography, 315-334
adenosine in, 323-324
in aortic stenosis, 483-484
arbutamine in, 323
bicycle, 309, 322
in cardiac transplantation, 326
computer-assisted, 321-322
contrast. *See* Echocardiography, contrast
dipyridamole in, 323-324, 353-354
dobutamine in. *See* Dobutamine
Doppler, 316-318
end points in, 319-321

Stress echocardiography (*Continued*)
exercise, 322-323
in global left ventricular dysfunction, 324-325
handgrip in, 322-323
historical background of, 316
left ventricular function assessment after, 346-347
in myocardial viability assessment, 326-327
in noncardiac preoperative risk assessment, 325-326
passive, 323-324
pharmacologic, 323-324
quantitative, in regional left ventricular dysfunction, 320
in regional wall abnormalities, 324-325
in segmental left ventricular dysfunction, 319-320
in segmental wall thickening, 320-321
vs. stress nuclear perfusion imaging, 328-329
clinical considerations in, 275-279
cost-effectiveness analysis of, 197-214
in coronary artery disease diagnosis, 201-206
cost definition in, 200-201
definition of, 198-199
economic perspective definition in, 199-200
in myocardial hibernation, 208-209
after myocardial infarction, 206-207
vs. other economic analytic methods, 198
overview of, 201
in preoperative risk assessment, 207-208
after revascularization, 207
outcomes research methods for, 215-230
anatomy-based vs. risk-based clinical strategies in, 227-228
appropriateness of, 228
clinical application of, 221
cost-effectiveness in, 223-227
endpoint selection in, 219-220, 226-227
incremental prognostic value in, 220-221
multivariable modeling in, 216
regression analysis in, 216
resource use measurement in, 228
in risk stratification, 221-223
survival analysis in, pitfalls of, 216-219
vs. technological approaches, 227
in preoperative risk assessment
cost-effectiveness analysis of, 207-208
prognostic value of, 240
prognostic comparisons of, 231-244, 275-279
jeopardized viable myocardium detection in, 232-236
low-risk patient identification in, 236-240
principles of, 232
in regional systolic function recovery prediction, 425
test selection, 275-279
with stress nuclear perfusion imaging, in single laboratory service, 363-372
Stress echocardiography (*Continued*)
stressors for, 322-323
technical considerations in, 303-314
bicycle, 309, 322
contraindications, 306
contrast, 311-312
environment for, 304
equipment arrangement, 305-306
exercise, 305-309
nonexercise, 309-311
principles, 303-305
procedure, 306-312
techniques for, 316-319, 321-322
three-dimensional, 319
transesophageal, 318-319
two-dimensional, 318
in valvular disease, 325
vasodilators in, 323-324, 354
Stress electrocardiography. *See* Electrocardiography, stress
Stroke
in cardiac surgery
from carotid emboli, 107-108
confusion in, 104-105
not waking in, 102-103
weakness in, 105-108
magnetic resonance imaging of. *See* Magnetic resonance imaging, of stroke
prognosis for, magnetic resonance imaging of, 132-133
progression of, magnetic resonance imaging of, 125-129
recovery from, magnetic resonance imaging of, 130-133
transcranial Doppler assessment of. *See* Transcranial Doppler assessment
Studies of Left Ventricular Dysfunction, 188, 438, 446-448
Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments, 260
Stunned myocardium, viability assessment of, 352, 354-355
Sudden death
in aortic stenosis, 478, 489
in ischemic heart failure, 434-435
in QT interval abnormalities
long QT syndrome, S12-S13
myocardial infarction, S13-S14
population studies of, S7-S12
SUPPORT (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatment), 260
Surgery, noncardiac, preoperative assessment for, myocardial perfusion scintigraphy in, 290-294

Survival analysis, in outcomes research, on noninvasive stress testing, pitfalls of, 216-219
Survival and Ventricular Survival study, 188
Swedish Trial in Old Patients (STOP) with Hypertension, 172-173, 181, 185
Syncope
  in aortic regurgitation, 470
  in aortic stenosis, 479
Syncytial cells, description of, 524
Systemic lupus erythematosus, autoimmunity in, left ventricular assist device immune response and, 72-73
Systolic function
  as myocardial viability standard, 421
  prediction of, echocardiography vs. radionuclide imaging in, 425
Systolic Hypertension in China study, 181, 185
Systolic Hypertension in Europe study, 181, 185
Systolic Hypertension in the Elderly Program, 183

T-cells, interactions of, with left ventricular assist devices, 68-71, 73-75
Tat protein, in endothelial cell dysfunction, in cardiomyopathy, in AIDS, 157
Tawara, Sunao, internodal pathway studies of, 495-496
Technetium-99m imaging, 288
  in emergency room, 294-295
  of myocardial hibernation, 423-424
  of myocardial viability, 357
Telephone follow-up, for heart failure outpatient-based care, 261-263
Terfenadine, QT interval prolongation due to, S16, S30-S33
Terodiline, QT interval prolongation due to, S33
Thalamus, stroke of, in cardiac surgery, 103
Thallium imaging, 282-284, 288-291, 293
  of myocardial hibernation, 421-423, 427-428
  of myocardial viability, 357
  vs. stress echocardiography, cost-effectiveness of, 203
Thioridazine, QT interval prolongation due to, S33-S34
Thorel, Charles, internodal pathway studies of, 496-497
Thrombolysis, in myocardial infarction, perfusion scintigraphy after, 288-289
Thrombosis
  with left ventricular assist device, 44
  prevention of, in ischemic heart failure, 445-448
TIBET (Total Ischaemic Burden European Trial), 173, 176
TOMH (Treatment of Mild Hypertension), 181, 185
Torsades de pointes, QT interval and, S7
Torus Loweri, 504
Total Ischaemic Burden European Trial, 173, 176
Toxic encephalopathy, in cardiac surgery, 102
Transcranial Doppler assessment, of cerebral embolic disorders, 135-150
  advantages of, 135
  artifacts in, 136-138
  of cardiac origin, 141-143
  emboli types in, 138-139
  microemboli, 139-141
  principles of, 135-136
  procedure-related, 143-145
  retinal ischemia, 139
  stroke, 139
  in treatment monitoring, 145
  in venous system, 145
Transesophageal echocardiography, 318-319
  in aortic stenosis, 484
  in left ventricular assist device placement, 49-50
Transitional cells
  description of, 515-516
  function of, 527, 529-530
  in His bundle and branches, 508-509
  vs. Purkinje cells, 508-511, 515-516, 530
Transplantation, cardiac
  bridge to. *See* Left ventricular assist devices, as bridge to transplantation
  costs of, vs. left ventricular assist device costs, 81-91
  donor shortage for, mechanical device development and, 1-4
  stress echocardiography in, 326
Treadmill, for stress echocardiography, 305-309, 322
Treatment of Mild Hypertension study, 181, 185
Trimethoprim, QT interval prolongation due to, S33
Tuberous sclerosis, Purkinje cell tumors in, 513
Tumor necrosis factor a, in cardiomyopathy, in AIDS, 155-156

Ultrasound
  contrast agents for, in echocardiography. *See* Echocardiography, contrast
  Doppler. *See* Transcranial Doppler assessment
United Kingdom-based Department of Health Hypertension Care Computing Project, 181

VADs. *See* Left ventricular assist devices; Ventricular assist devices
Valvular disease. *See also specific valves*
  emboli from, transcranial Doppler assessment of, 141-142
  left ventricular assist device with, 39-40
  stress echocardiography in, 325
VAMI (Verapamil in Acute Myocardial Infarction) trial, 177
Vascular changes, in cardiomyopathy, in AIDS, 156-157
Vascular disease, calcium channel blocker safety in, 179-181
Vasodilator-Heart Failure Trial study, 184, 186, 445

Vasodilators
in echocardiography, 323-324, 354
in ischemic heart failure, 444
in mitral regurgitation, 466
Vena contracta method, in mitral regurgitation quantification, 465
Ventricle(s)
left. *See* Left ventricle(s)
right
arrhythmogenic dysplasia of, apoptosis in, 517-520
dysfunction of
with left ventricular assist device, 43
during left ventricular assist device placement, 51
Ventricular assist devices. *See also* Left ventricular assist devices
discharge protocol for, 58-59
history of, 1-4
patient education for, 57-58
Ventricular ectopy, in preoperative cardiac event prediction, 292-293
Ventriculography
in aortic regurgitation, 471
in mitral regurgitation, 465-466
in postexercise left ventricular function assessment
first-pass, 339-340
multiple-gated, 335-339
Verapamil, safety of
in angina, 173, 175-176
in hypertension, 182-183
Verapamil, safety of (*Continued*)
mortality rate and, 187
in myocardial infarction, 177-179
in vascular disease, 179-181
Verapamil in Acute Myocardial Infarction trial, 177
Verapamil in Hypertension and Atherosclerosis Study, 179-181
Verapamil Infarction Study on Remodeling and Relaxation, 177
Vertebral arteries, stroke involving, in cardiac surgery, 103
VHAS (Verapamil in Hypertension and Atherosclerosis Study), 179-181
Viability, myocardial. *See* Myocardial viability
VISOR (Verapamil Infarction Study on Remodeling and Relaxation), 177

Warfarin, in ischemic heart failure, 445-448
Water, oxygen-15 labeled, in PET, of myocardial ischemia, 403-406
Weakness, in cardiac surgery, 105-109
Wenckebach, K.F., internodal pathway studies of, 495, 497
Wolff-Parkinson-White syndrome, pathophysiology of, 503
Women, myocardial perfusion scintigraphy in, 294

Zidovudine, for AIDS, cardiomyopathy and, 157-158
Ziprasidone, QT interval prolongation due to, S34